Advertisement

Delta Opioid Receptor (DOR) Ligands and Pharmacology: Development of Indolo- and Quinolinomorphinan Derivatives Based on the Message-Address Concept

Chapter
First Online:
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 247)

Abstract

The pharmacology of the delta opioid receptor (DOR) has lagged, mainly due to the lack of an agonist with high potency and selectivity in vivo. The DOR is now receiving increasing attention, and there has been progress in the synthesis of better novel ligands. The discovery of a selective receptor DOR antagonist, naltrindole (NTI), stimulated the design and synthesis of (±)TAN-67, which was designed based on the message-address concept and the accessory site theory. Intensive studies using (±)TAN-67 determined the DOR-mediated various pharmacological effects, such as antinociceptive effects for painful diabetic neuropathy and cardiovascular protective effects. We improved the agonist activity of TAN-67 to afford SN-28, which was modified to KNT-127, a novel compound that improved the blood–brain barrier permeability. In addition, KNT-127 showed higher selectivity for the DOR and had potent agonist activity following systemic administration. Interestingly, KNT-127 produced no convulsive effects, unlike prototype DOR agonists. The KNT-127 type derivatives with a quinolinomorphinan structure are expected to be promising candidates for the development of therapeutic DOR agonists.

Keywords

(−)TAN-67 Analgesic Antidepressant Antitussive Anxiolytic TRK-850 δ Opioid receptor 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We thank Prof. Tsutomu Suzuki, Prof. Junzo Kamei, Prof. Minoru Narita, (Hoshi University), Prof. Hideaki Fujii (Kitasato University), and Director Mitsuhiko Yamada (National Center of Neurology and Psychiatry) for their continuous support of research on the DOR ligand and its pharmacology.

References

  1. Chiang T, Sansuk K, van Rijn RM (2016) Beta-arrestin 2 dependence of delta opioid receptor agonists is correlated with alcohol intake. Br J Pharmacol 173(2):332–343Google Scholar
  2. Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang KJ, De Costa BR, Mosberg HI, Woods JH (1993) Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 267:888–895Google Scholar
  3. Cryan JF, Valentino RJ, Lucki I (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29:547–569CrossRefGoogle Scholar
  4. Fernyhough P, Calcutt NA (2010) Abnormal calcium homeostasis in peripheral neuropathies. Cell Calcium 47:130–139CrossRefGoogle Scholar
  5. Fryer RM, Hsu AK, Eells JT, Nagase H, Gross GJ (1999) Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res 84:846–851CrossRefGoogle Scholar
  6. Fryer RM, Auchampach JA, Gross GJ (2002) Therapeutic receptor targets of ischemic preconditioning. Cardiovasc Res 55:520–525CrossRefGoogle Scholar
  7. Fujii H, Takahashi T, Nagase H (2013) Non-peptidic δ opioid receptor agonists and antagonists (2000–2012). Expert Opin Ther Pat 23:1181–1208CrossRefGoogle Scholar
  8. Huh J, Gross GJ, Nagase H, Liang BT (2001) Protection of cardiac myocytes via delta(1)-opioid receptors, protein kinase C, and mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 280:H377–H383CrossRefGoogle Scholar
  9. Jutkiewicz EM, Eller EB, Folk JE, Rice KC, Traynor JR, Woods JH (2004) Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J Pharmacol Exp Ther 309:173–181CrossRefGoogle Scholar
  10. Kamei J (1996) Role of opioidergic and serotonergic mechanisms in cough and antitussives. Pulm Pharmacol 9:349–356CrossRefGoogle Scholar
  11. Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y (1994) Streptozotocin-induced diabetes selectively enhances antinociception mediated by delta 1- but not delta 2-opioid receptors. Life Sci 55:L121–L126CrossRefGoogle Scholar
  12. Kamei J, Saitoh A, Ohsawa M, Suzuki T, Misawa M, Nagase H, Kasuya Y (1995) Antinociceptive effects of the selective non-peptidic delta-opioid receptor agonist TAN-67 in diabetic mice. Eur J Pharmacol 276:131–135CrossRefGoogle Scholar
  13. Kamei J, Kawai K, Mizusuna A, Saitoh A, Morita K, Narita M, Tseng LF, Nagase H (1997) Supraspinal delta 1-opioid receptor-mediated antinociceptive properties of (-)-TAN-67 in diabetic mice. Eur J Pharmacol 322:27–30CrossRefGoogle Scholar
  14. Kamei J, Ohsawa M, Suzuki T, Saitoh A, Endoh T, Narita M, Tseng LF, Nagase H (1999) The modulatory effect of (+)-TAN-67 on the antinociceptive effects of the nociceptin/orphanin FQ in mice. Eur J Pharmacol 383:241–247CrossRefGoogle Scholar
  15. Knapp RJ, Landsman R, Waite S, Malatynska E, Varga E, Haq W, Hruby VJ, Roeske WR, Nagase H, Yamamura HI (1995) Properties of TAN-67, a nonpeptidic delta-opioid receptor agonist, at cloned human delta- and mu-opioid receptors. Eur J Pharmacol 291:129–134CrossRefGoogle Scholar
  16. Krishnan-Sarin S, Jing SL, Kurtz DL, Zweifel M, Portoghese PS, Li TK, Froehlich JC (1995a) The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berl) 120:177–185CrossRefGoogle Scholar
  17. Krishnan-Sarin S, Portoghese PS, Li TK, Froehlich JC (1995b) The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol Biochem Behav 52:153–159CrossRefGoogle Scholar
  18. Lê AD, Poulos CX, Quan B, Chow S (1993) The effects of selective blockade of delta and mu opiate receptors on ethanol consumption by C57BL/6 mice in a restricted access paradigm. Brain Res 630:330–332CrossRefGoogle Scholar
  19. Levy J, Gavin JR, Sowers JR (1994) Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med 96:260–273CrossRefGoogle Scholar
  20. Matsuzawa S, Suzuki T, Misawa M, Nagase H (1999) Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress. Eur J Pharmacol 368:9–16CrossRefGoogle Scholar
  21. Nagase H, Fujii H (2011) Opioids in preclinical and clinical trials. Top Curr Chem 299:29–62CrossRefGoogle Scholar
  22. Nagase H, Kawai K, Hayakawa J, Wakita H, Mizusuna A, Matsuura H, Tajima C, Takezawa Y, Endoh T (1998) Rational drug design and synthesis of a highly selective nonpeptide delta-opioid agonist, (4aS*,12aR*)-4a-(3-hydroxyphenyl)-2-methyl- 1,2,3,4,4a,5,12,12a-octahydropyrido[3,4-b]acridine (TAN-67). Chem Pharm Bull (Tokyo) 46:1695–1702CrossRefGoogle Scholar
  23. Nagase H, Yajima Y, Fujii H, Kawamura K, Narita M, Kamei J, Suzuki T (2001) The pharmacological profile of delta opioid receptor ligands, (+) and (-) TAN-67 on pain modulation. Life Sci 68:2227–2231CrossRefGoogle Scholar
  24. Nagase H, Osa Y, Nemoto T, Fujii H, Imai M, Nakamura T, Kanemasa T, Kato A, Gouda H, Hirono S (2009) Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett 19:2792–2795CrossRefGoogle Scholar
  25. Nagase H, Nemoto T, Matsubara A, Saito M, Yamamoto N, Osa Y, Hirayama S, Nakajima M, Nakao K, Mochizuki H, Fujii H (2010) Design and synthesis of KNT-127, a delta-opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett 20:6302–6305CrossRefGoogle Scholar
  26. Nakata E, Sakai J, Kanda T, Watanabe T, Saito D, Takahashi T, Iwai T, Hirayama S, Fujii H, Yamakawa T, Nagase H (2014) Receptor-mediated beta-arrestin signaling modulates convulsive effects. In: International narcotic research conference 2014, p 63Google Scholar
  27. Negus SS, Butelman ER, Chang KJ, DeCosta B, Winger G, Woods JH (1994) Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J Pharmacol Exp Ther 270:1025–1034Google Scholar
  28. Nozaki C, Le Bourdonnec B, Reiss D, Windh RT, Little PJ, Dolle RE, Kieffer BL, Gavériaux-Ruff C (2012) δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J Pharmacol Exp Ther 342:799–807CrossRefGoogle Scholar
  29. Nozaki C, Nagase H, Nemoto T, Matifas A, Kieffer BL, Gaveriaux-Ruff C (2014) In vivo properties of KNT-127, a novel δ opioid receptor agonist: receptor internalization, antihyperalgesia and antidepressant effects in mice. Br J Pharmacol 171:5376–5386CrossRefGoogle Scholar
  30. Ohsawa M, Nagase H, Kamei J (1998) Role of intracellular calcium in modification of mu and delta opioid receptor-mediated antinociception by diabetes in mice. J Pharmacol Exp Ther 286:780–787PubMedGoogle Scholar
  31. Peart JN, Patel HH, Gross GJ (2003) Delta-opioid receptor activation mimics ischemic preconditioning in the canine heart. J Cardiovasc Pharmacol 42:78–81CrossRefGoogle Scholar
  32. Portoghese PS, Sultana M, Nagase H, Takemori AE (1988) Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem 31:281–282CrossRefGoogle Scholar
  33. Portoghese PS, Sultana M, Takemori AE (1990) Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. J Med Chem 33:1714–1720CrossRefGoogle Scholar
  34. Pradhan AA, Becker JA, Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Massotte D, Gavériaux-Ruff C, Kieffer BL (2009) In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS One 4:e5425CrossRefGoogle Scholar
  35. Pradhan AA, Walwyn W, Nozaki C, Filliol D, Erbs E, Matifas A, Evans C, Kieffer BL (2010) Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci 30:16459–16468CrossRefGoogle Scholar
  36. Roberts AJ, Gold LH, Polis I, McDonald JS, Filliol D, Kieffer BL, Koob GF (2001) Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol Clin Exp Res 25:1249–1256PubMedGoogle Scholar
  37. Saitoh A, Yamada M (2012) Antidepressant-like effects of delta opioid receptor agonists in animal models. Curr Neuropharmacol 10:231–238CrossRefGoogle Scholar
  38. Saitoh A, Sugiyama A, Nemoto T, Fujii H, Wada K, Oka J, Nagase H, Yamada M (2011) The novel delta opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions. Behav Brain Res 223:271–279CrossRefGoogle Scholar
  39. Saitoh A, Sugiyama A, Yamada M, Inagaki M, Oka J, Nagase H (2013) The novel δ opioid receptor agonist KNT-127 produces distinct anxiolytic-like effects in rats without producing the adverse effects associated with benzodiazepines. Neuropharmacology 67:485–493CrossRefGoogle Scholar
  40. Sakami S, Kawai K, Maeda M, Aoki T, Fujii H, Ohno H, Ito T, Saitoh A, Nakao K, Izumimoto N, Matsuura H, Endo T, Ueno S, Natsume K, Nagase H (2008) Design and synthesis of a metabolically stable and potent antitussive agent, a novel delta opioid receptor antagonist, TRK-851. Bioorg Med Chem 16:7956–7967CrossRefGoogle Scholar
  41. Schultz JE, Hsu AK, Gross GJ (1998) Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. Circulation 97:1282–1289CrossRefGoogle Scholar
  42. Schwyzer R (1977) ACTH: a short introductory review. Ann N Y Acad Sci 297:3–26CrossRefGoogle Scholar
  43. Sugiyama A, Nagase H, Oka J, Yamada M, Saitoh A (2014) DOR(2)-selective but not DOR(1)-selective antagonist abolishes anxiolytic-like effects of the δ opioid receptor agonist KNT-127. Neuropharmacology 79:314–320CrossRefGoogle Scholar
  44. Suzuki T, Tsuji M, Mori T, Misawa M, Endoh T, Nagase H (1995) Effects of a highly selective nonpeptide delta opioid receptor agonist, TAN-67, on morphine-induced antinociception in mice. Life Sci 57:155–168CrossRefGoogle Scholar
  45. Suzuki T, Tsuji M, Mori T, Misawa M, Endoh T, Nagase H (1996) Effect of the highly selective and nonpeptide delta opioid receptor agonist TAN-67 on the morphine-induced place preference in mice. J Pharmacol Exp Ther 279:177–185PubMedGoogle Scholar
  46. Tanahashi S, Ueda Y, Nakajima A, Yamamura S, Nagase H, Okada M (2012) Novel δ1-receptor agonist KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex. Neuropharmacology 62:2057–2067CrossRefGoogle Scholar
  47. Tseng LF, Narita M, Mizoguchi H, Kawai K, Mizusuna A, Kamei J, Suzuki T, Nagase H (1997) Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord. J Pharmacol Exp Ther 280:600–605PubMedGoogle Scholar
  48. van Ree JM, Gerrits MA, Vanderschuren LJ (1999) Opioids, reward and addiction: An encounter of biology, psychology, and medicine. Pharmacol Rev 51:341–396PubMedGoogle Scholar
  49. van Rijn RM, Whistler JL (2009) The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol Psychiatry 66:777–784CrossRefGoogle Scholar
  50. van Rijn RM, Brissett DI, Whistler JL (2010) Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety. J Pharmacol Exp Ther 335:133–139CrossRefGoogle Scholar
  51. van Rijn RM, Brissett DI, Whistler JL (2012) Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists. Drug Alcohol Depend 122:156–159CrossRefGoogle Scholar
  52. Violin JD (2014) Biased ligands at mu and delta opioid receptors: targeting selective signalling to develop improved therapeutics. In: International narcotic research conference 2014, p 22Google Scholar
  53. Violin JD, Crombie AL, Soergel DG, Lark MW (2014) Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 35:308–316CrossRefGoogle Scholar
  54. Yajima Y, Narita M, Tsuda M, Imai S, Kamei J, Nagase H, Suzuki T (2000) Modulation of NMDA- and (+)TAN-67-induced nociception by GABA(B) receptors in the mouse spinal cord. Life Sci 68:719–725CrossRefGoogle Scholar

Copyright information

© SpringerInternationalPublishingSwitzerland 2016

Authors and Affiliations

  1. 1.Department of NeuropsychopharmacologyNational Center of Neurology and Psychiatry, National Institute of Mental HealthTokyoJapan
  2. 2.International Institute for Integrative Sleep Medicine (WPI-IIIS), University of TsukubaTsukubaJapan

Personalised recommendations

Cite chapter